Enzo Reaches Marketing Deal for IncellDx's HPV Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Enzo Biochem announced today that its Enzo Clinical Labs subsidiary has reached a deal to market a test based on IncellDx's HPV OncoTect technology.

HPV OncoTect will be validated in-house at Enzo Clinical labs, after which the company will seek approval in New York State to market the assay as a laboratory-developed test. If approved, Enzo would become the first New York licensed reference lab offering the test, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.